Abstract
Immunotherapy with chimeric antigen receptor T (CAR-T) cells has proved remarkably
effective in recently published clinical trials. In this meta-analysis, we performed
a systematic review in terms of the clinical response treated with CAR-T cells in
acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and lymphomas
patients. Thirty-eight published clinical studies including 665 patients were eligible
for response rate (RR) evaluation. The overall pooled RR of CD19-CAR-T cells was 72%
(95% confidence interval: 62–77%). The various clinical parameters were analyzed.
RR was 81% in ALL, 68% in lymphoma and 70% in CLL. RR in patients who received interleukin
(IL)-2 was 70%, whereas in those who did not receive IL-2, it was 74%. RR was 75%
with lymphodepletion and 56% without lymphodepletion. RR with autologous cells was
76% and 57% with allogeneic cells. In conclusion, this meta-analysis showed a high
clinical RR of CD19-CAR-T cell–based immunotherapy in patients with refractory B-cell
malignancies.
Key Words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Off the shelf T cell therapies for hematologic malignancies.Best Pract Res Clin Haematol. 2018; 31 (Epub 2018 Mar 28): 166-175https://doi.org/10.1016/j.beha.2018.03.001
- Chimeric antigen receptor T-cells for B-cell malignancies.Transl Res. 2017; 187 (Epub 2017 Jun 29): 59-82https://doi.org/10.1016/j.trsl.2017.06.011
- CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).Ther Adv Hematol. 2015; 6: 228-241https://doi.org/10.1177/2040620715588916
- CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.Blood. 2016; 127 (Epub 2016 May 20): 3312-3320https://doi.org/10.1182/blood-2016-02-629063
- A Milestone for CAR T Cells.N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2593-2596https://doi.org/10.1056/NEJMe1714680
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med. 2018; 378: 439-448https://doi.org/10.1056/NEJMoa1709866
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2531-2544https://doi.org/10.1056/NEJMoa1707447
- Correlation of patient characteristics and biomarkers with clinical outcomes of JCAR017 in R/R aggressive B-NHL (TRANSCEND NHL 001 study).Journal of Clinical Oncology. 2018; 36 (122-122)
- Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials.Leuk Lymphoma. 2013; 54 (Epub 2012 Sep 8): 255-260https://doi.org/10.3109/10428194.2012.715350
- Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.Eur J Haematol. 2016; 96 (Epub 2015 Jul 3): 389-396https://doi.org/10.1111/ejh.12602
- Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.Oncotarget. 2015; 6: 33961-33971https://doi.org/10.18632/oncotarget.5582
- Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.Immunotherapy. 2017; 9: 979-993https://doi.org/10.2217/imt-2017-0062
- Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety.Curr Med Chem. 2017; ([Epub ahead of print])https://doi.org/10.2174/0929867324666170801101842
- The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.Ann Hematol. 2018; ([Epub ahead of print])https://doi.org/10.1007/s00277-018-3368-8
- A guide to manufacturing CAR T cell therapies.Curr Opin Biotechnol. 2018; 53 (Epub 2018 Feb 18): 164-181https://doi.org/10.1016/j.copbio.2018.01.025
- Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.Drugs Today (Barc). 2018; 54: 187-198https://doi.org/10.1358/dot.2018.54.3.2776625
- Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.Biol Blood Marrow Transplant. 2010; 16 (Epub 2010 Mar 19): 1245-1256https://doi.org/10.1016/j.bbmt.2010.03.014
- Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.J Clin Oncol. 2015; 33 (Epub 2014 Aug 25): 540-549https://doi.org/10.1200/JCO.2014.56.2025
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood. 2010; 116 (Epub 2010 Jul 28): 4099-4102https://doi.org/10.1182/blood-2010-04-281931
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.Blood. 2013; 122 (Epub 2013 Sep 20): 4129-4139https://doi.org/10.1182/blood-2013-08-519413
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.Blood. 2012; 119 (Epub 2011 Dec 8): 2709-2720https://doi.org/10.1182/blood-2011-10-384388
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.Blood. 2011; 118 (Epub 2011 Aug 17): 4817-4828https://doi.org/10.1182/blood-2011-04-348540
- T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.Sci Transl Med. 2011; 3: 95ra73https://doi.org/10.1126/scitranslmed.3002842
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.J Clin Invest. 2011; 121 (Epub 2011 Apr 11): 1822-1826https://doi.org/10.1172/JCI46110
- CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.Sci Transl Med. 2013; 5: 177ra38https://doi.org/10.1126/scitranslmed.3005930
- Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N Engl J Med. 2013; 368 (Epub 2013 Mar 25): 1509-1518https://doi.org/10.1056/NEJMoa1215134
- Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.Sci Transl Med. 2014; 6: 224ra25https://doi.org/10.1126/scitranslmed.3008226
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.Lancet. 2015; 385 (Epub 2014 Oct 13): 517-528https://doi.org/10.1016/S0140-6736(14)61403-3
- Chimeric antigen receptor T cells for sustained remissions in leukemia.N Engl J Med. 2014 Oct 16; 371: 1507-1517https://doi.org/10.1056/NEJMoa1407222
- Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.Blood. 2013; 122 (Epub 2013 Sep 12): 2965-2973https://doi.org/10.1182/blood-2013-06-506741
- Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med. 2011 Aug 25; 365 (Epub 2011 Aug 10): 725-733https://doi.org/10.1056/NEJMoa1103849
- Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.Blood. 2016; 127 (Epub 2016 Feb 23): 2406-2410https://doi.org/10.1182/blood-2015-08-665547
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.J Clin Invest. 2016; 126 (Epub 2016 Aug 2): 3363-3376https://doi.org/10.1172/JCI86721
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.J Clin Oncol. 2016; 34 (Epub 2016 Jan 25): 1112-1121https://doi.org/10.1200/JCO.2015.64.5929
- Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Oncoimmunology. 2015; 4 (eCollection 2015 Nov)e1027469
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.N Engl J Med. 2015; 373: 1040-1047https://doi.org/10.1056/NEJMoa1504542
- Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.Blood. 2016; 127 (Epub 2016 Jan 26): 1117-1127https://doi.org/10.1182/blood-2015-11-679134
- CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.J Clin Invest. 2016; 126 (Epub 2016 Apr 25): 2123-2138https://doi.org/10.1172/JCI85309
- Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.Blood. 2016; 128 (Epub 2016 May 10): 360-370https://doi.org/10.1182/blood-2016-01-694356
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.Sci Transl Med. 2015; 7: 303ra139https://doi.org/10.1126/scitranslmed.aac5415
- Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.Clin Cancer Res. 2017; 23 (Epub 2016 Dec 30): 3297-3306https://doi.org/10.1158/1078-0432.CCR-16-1799
- Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.Sci Transl Med. 2016; 8: 355ra116https://doi.org/10.1126/scitranslmed.aaf8621
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.Blood. 2016; 127 (Epub 2016 Apr 26): 2980-2990https://doi.org/10.1182/blood-2015-12-686725
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.J Clin Oncol. 2017; 35 (Epub 2017 Mar 14): 1803-1813https://doi.org/10.1200/JCO.2016.71.3024
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.Mol Ther. 2017; 25 (Epub 2017 Jan 4): 285-295https://doi.org/10.1016/j.ymthe.2016.10.020
- Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.Br J Haematol. 2017; 179 (Epub 2017 Oct 26): 598-605https://doi.org/10.1111/bjh.14923
- In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.Mol Ther. 2018; 26 (Epub 2018 Feb 2): 976-985https://doi.org/10.1016/j.ymthe.2018.01.022
- Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia.Am J Hematol. 2018; 93 (Epub 2018 Apr 28): 851-858https://doi.org/10.1002/ajh.25108
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2545-2554https://doi.org/10.1056/NEJMoa1708566
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.N Engl J Med. 2018; 378: 449-459https://doi.org/10.1056/NEJMoa1709919
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.N Engl J Med. 2017; 377 (Epub 2017 Dec 10): 2531-2544https://doi.org/10.1056/NEJMoa1707447
- CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study.Ann Hematol. 2018; 97 (Epub 2018 Feb 7): 781-789https://doi.org/10.1007/s00277-018-3246-4
- Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.Blood. 2017; 129 (Epub 2017 Apr 13): 3322-3331https://doi.org/10.1182/blood-2017-02-769208
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.J Clin Oncol. 2017; 35 (Epub 2017 Jul 17): 3010-3020https://doi.org/10.1200/JCO.2017.72.8519
- The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis.BMC Cancer. 2018; 18: 929https://doi.org/10.1186/s12885-018-4817-4
- Adoptive cell transfer as personalized immunotherapy for human cancer.Science. 2015; 348: 62-68https://doi.org/10.1126/science.aaa4967
- Chimeric antigen receptor T-cell therapies for lymphoma.Nat Rev Clin Oncol. 2018; 15 (Epub 2017 Aug 31): 31-46https://doi.org/10.1038/nrclinonc.2017.128
- Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review.Immunotherapy. 2017; 9: 123-130https://doi.org/10.2217/imt-2016-0127
Article info
Publication history
Published online: May 31, 2019
Accepted:
April 9,
2019
Received:
December 12,
2018
Identification
Copyright
© 2019 International Society for Cell and Gene Therapy. Published by Elsevier Inc. All rights reserved.
